2025
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias
Kim W, Crosse E, De Neef E, Etxeberria I, Sabio E, Wang E, Bewersdorf J, Lin K, Lu S, Belleville A, Fox N, Castro C, Zhang P, Fujino T, Lewis J, Rahman J, Zhang B, Winick J, Lewis A, Stanley R, DeWolf S, Urben B, Takizawa M, Krause T, Molina H, Chaligne R, Koppikar P, Molldrem J, Gigoux M, Merghoub T, Daniyan A, Chandran S, Greenbaum B, Klebanoff C, Bradley R, Abdel-Wahab O. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell 2025, 188: 3422-3440.e24. PMID: 40273911, PMCID: PMC12204805, DOI: 10.1016/j.cell.2025.03.047.Peer-Reviewed Original ResearchConceptsT cell receptorT cellsCurative allogeneic stem cell transplantationVirus-reactive T cellsAllogeneic stem cell transplantationCD8<sup>+</sup> T cellsCognate T cell receptorsStem cell transplantationBlood of patientsImpaired cytotoxic functionPeptide-major histocompatibility complexMyeloid malignanciesCell transplantationActive cancerCytotoxic functionMyeloid leukemiaHealthy donorsPublic neoantigensNeoantigensHistocompatibility complexSplicing alterationsLeukemiaMis-splicing eventsRNA splicing factorsPatientsNatural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes
Rodriguez-Sevilla J, Ganan-Gomez I, Kumar B, Thongon N, Ma F, Chien K, Kim Y, Yang H, Loghavi S, Tan R, Adema V, Li Z, Tanaka T, Uryu H, Kanagal-Shamanna R, Al-Atrash G, Bejar R, Banerjee P, Lynn Cha S, Montalban-Bravo G, Dougherty M, Fernandez Laurita M, Wheeler N, Jia B, Papapetrou E, Izzo F, Dueñas D, McAllen S, Gu Y, Todisco G, Ficara F, Della Porta M, Jain A, Takahashi K, Clise-Dwyer K, Halene S, Bertilaccio M, Garcia-Manero G, Daher M, Colla S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature Communications 2025, 16: 3450. PMID: 40216768, PMCID: PMC11992119, DOI: 10.1038/s41467-025-58662-0.Peer-Reviewed Original ResearchConceptsHematopoietic stem cellsMyelodysplastic syndromeImmune escapeMyelodysplastic syndrome hematopoietic stem cellsNatural killer (NK) cellsAberrant hematopoietic stem cellsEarly-stage myelodysplastic syndromeDevelopment of myelodysplastic syndromeStage of myelodysplastic syndromeAdoptive cell therapyFunctional in vitro studiesNatural killer cellsTime of diagnosisPreclinical in vivo studiesPre-malignant clonesDisease-related comorbiditiesPre-malignant stageSlow down disease progressionRegenerate hematopoiesisClonal cytopeniaNK cellsImmune surveillanceKiller cellsHealthy donorsPharmacological therapyMMP9High Neutrophils are Critical Mediators of Neutrophil Extracellular Traps Formation and Myocardial Ischemia/Reperfusion Injury
Hu S, Zhang F, Wang J, Zhang J, Li C, Lyu Y, Wang Y, Huang R, Gao Y, Yang H, Qian J, Tang W, Cao J, Ge J. MMP9High Neutrophils are Critical Mediators of Neutrophil Extracellular Traps Formation and Myocardial Ischemia/Reperfusion Injury. Advanced Science 2025, 12: 2415205. PMID: 40151877, PMCID: PMC12140383, DOI: 10.1002/advs.202415205.Peer-Reviewed Original ResearchConceptsNeutrophil extracellular trap formationNeutrophil extracellular trapsMyocardial ischemia/reperfusion injuryIschemia/reperfusion injuryBlood of healthy donorsNeutrophil-mediated reperfusion injuryTherapeutic targetExtracellular trap formationTranscription factor SPI1Potential therapeutic targetHealthy donors
2024
Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
Najarro G, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Hofmeister C. Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade. Blood 2024, 144: 5142-5142. DOI: 10.1182/blood-2024-202078.Peer-Reviewed Original ResearchFree light chain ratioLight chain ratioSerum free light chain ratioSerum free light chainsFLC ratioFree light chainsFreelite assayChain ratioCKD-EPIHistory of lymphoproliferative disordersThermo FisherLight chainPeriod of 6-monthsMedian valueYears of agePlasma cell productionLymphoproliferative disordersAlpha 1-antitrypsinPrevent MMHealthy donorsLymphoproliferative diseaseBlood testsRenal clearanceSerum concentrationsEGFRMis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
Kim W, Crosse E, De Neef E, Etxeberria I, Sabio E, Wang E, Bewersdorf J, Lu S, Belleville A, Fox N, Castro C, Zhang P, Fujino T, Lewis J, Rahman J, Zhang B, Winick J, Lewis A, Stanley R, Dewolf S, Meskauskaite Urben B, Takizawa M, Krause T, Molina H, Chaligne R, Koppikar P, Molldrem J, Gigoux M, Merghoub T, Daniyan A, Greenbaum B, Klebanoff C, Bradley R, Abdel-Wahab O. Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms. Blood 2024, 144: 343-343. DOI: 10.1182/blood-2024-198639.Peer-Reviewed Original ResearchCD8+ T cellsT cell receptorPrimary human T cellsHuman T cellsT cellsHLA-ILeukemic cellsSRSF2 mutationsHealthy donorsIsolated CD8+ T cellsGraft-versus-leukemia effectT cell cytotoxic functionTCR-T cell therapyVirus-reactive T cellsAllogeneic stem cell transplantationT cell-based immunotherapyT cell receptor clonotypesLyse leukemic cellsPatient PBMC samplesCognate T cell receptorsDonor T cellsHigh-risk MDSStem cell transplantationHLA class IMis-splicingZinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease
Lessard S, Rimmelé P, Ling H, Moran K, Vieira B, Lin Y, Rajani G, Hong V, Reik A, Boismenu R, Hsu B, Chen M, Cockroft B, Uchida N, Tisdale J, Alavi A, Krishnamurti L, Abedi M, Galeon I, Reiner D, Wang L, Ramezi A, Rendo P, Walters M, Levasseur D, Peters R, Harris T, Hicks A. Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease. Scientific Reports 2024, 14: 24298. PMID: 39414860, PMCID: PMC11484757, DOI: 10.1038/s41598-024-74716-7.Peer-Reviewed Original ResearchConceptsHematopoietic stem cellsSickle cell diseaseTreatment of sickle cell diseaseFetal hemoglobinCell therapyReactivation of fetal hemoglobinCell diseaseMonths of follow-upStem cellsReactivate fetal hemoglobinResults of preclinical studiesPotential treatmentEngraftment in vivoAutologous cell therapyNovel cell therapiesVaso-occlusive crisisIncreased total hemoglobinErythroid progenyHealthy donorsPreclinical studiesClinical developmentFollow-upErythroid enhancerBCL11A erythroid enhancerGATAA motifsFlow cytometry for RBC damage and complement activation
Villalba C, Yurtsever N, Paternoster K, Gallipoli P, Nash B, Bizzario L, Shah B, Rinder H, Tormey C, Lee E. Flow cytometry for RBC damage and complement activation. American Journal Of Clinical Pathology 2024, 162: s182-s183. DOI: 10.1093/ajcp/aqae129.400.Peer-Reviewed Original ResearchDirect antiglobulin testRed blood cellsTukey HSD testHSD testAntiglobulin testComplement depositionOne-way ANOVANegative direct antiglobulin testFlow cytometryRed blood cell clearanceStatistically significant differenceTwo-sample t-testPercentage of red blood cellsExposure of PSHealthy donorsDiluted red blood cellsRBC recoveryRBC unitsPhosphatidylserine expressionRBC injuryFlow cytometry assayHealthy individualsPS expressionRed blood cell ageComplement activationNanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts
Li Y, Saba L, Scheinman R, Banda N, Holers M, Monte A, Dylla L, Moghimi S, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano 2024, 18: 28649-28658. PMID: 39395006, PMCID: PMC11651220, DOI: 10.1021/acsnano.4c05087.Peer-Reviewed Original ResearchConceptsPegylated Liposomal DoxorubicinComplement activationPredictive valuePlasma concentrationsC-reactive protein levelsAnti-PEG IgGTriggers proinflammatory responsesAnti-PEG IgMEfficacy of nanomedicinesPoor predictive valueAnti-PEG antibodiesLiposomal doxorubicinIron oxide nanowormsHealthy donorsHigher complement activationAcute infectionInflammatory disease conditionsChronic inflammationProinflammatory responseSystemic administrationComplement cascadeComplement factorsComplement responseIgMProtein levelsCholesterol promotes IFNG mRNA expression in CD4+ effector/memory cells by SGK1 activation
Hanin A, Comi M, Sumida T, Hafler D. Cholesterol promotes IFNG mRNA expression in CD4+ effector/memory cells by SGK1 activation. Life Science Alliance 2024, 7: e202402890. PMID: 39366761, PMCID: PMC11452476, DOI: 10.26508/lsa.202402890.Peer-Reviewed Original ResearchConceptsCentral nervous systemT cellsEffector/memory cellsCentral nervous system milieuT cell environmentCD4 T cellsIFNG mRNA expressionCXCR3<sup>+</sup> cellsT cell homeostasisInhibition of SGK1Targeting lipid pathwaysMaintenance of immune surveillanceSerum/glucocorticoid-regulated kinaseImmune surveillanceHealthy donorsCytotoxic capacityEffector responsesInflammatory conditionsSGK1 activityMRNA expressionNervous systemSGK1Metabolic conditionsLipid pathwaysTissue adaptationOptimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin
Li Y, Ettah U, Jacques S, Gaikwad H, Monte A, Dylla L, Guntupalli S, Moghimi S, Simberg D. Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin. Molecular Pharmaceutics 2024, 21: 3053-3060. PMID: 38743264, PMCID: PMC12109707, DOI: 10.1021/acs.molpharmaceut.4c00278.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayLiposomal doxorubicinHealthy donorsPatients treated with pegylated liposomal doxorubicinEnzyme-linked immunosorbent assay signalCancer patientsAnti-PEG IgGPegylated Liposomal DoxorubicinImmunosorbent assayOptimized ELISAEnzyme-linked immunosorbent assay protocolsAnti-PEG antibodiesChemotherapy cyclesBetween-assay variabilityPEGylated liposomesCutoff valueAccelerated clearanceTreatment cyclesDrug delivery systemsAntibody titersComplement activationInfused drugAnti-PEGOptimized assayPatientsAbstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)
Choo J, Tan W, Luk L, Zeng J, Soh T, Soon S, Lieow J, Wong C, Pang M, Bari S, Poon M, Koh L, Chng W, Jeyasekharan A, Tan L, Chan E, Sundar R. Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial). Cancer Research 2024, 84: ct160-ct160. DOI: 10.1158/1538-7445.am2024-ct160.Peer-Reviewed Original ResearchAdoptive cellular therapyPhase I studyHematologic malignanciesSolid tumorsCellular infusionT cellsHealthy donorsAmerican Association for Cancer Research annual meetingsDose levelsRecommended phase 2 doseTreatment of hematological malignanciesPhase 2 dosePoor marrow functionSubcutaneous IL-2Treatment-refractory tumorsDose-limiting toxicityPeripheral blood mononuclear cellsPre-treated patientsT-cell therapyPre-clinical dataBlood mononuclear cellsT cell survivalEnrollment of patientsDiverse tissue originDose escalation
2023
Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections
Jeffries L, Mis E, McWalter K, Donkervoort S, Brodsky N, Carpier J, Ji W, Ionita C, Roy B, Morrow J, Darbinyan A, Iyer K, Aul R, Banka S, Chao K, Cobbold L, Cohen S, Custodio H, Drummond-Borg M, Elmslie F, Finanger E, Hainline B, Helbig I, Hewson S, Hu Y, Jackson A, Josifova D, Konstantino M, Leach M, Mak B, McCormick D, McGee E, Nelson S, Nguyen J, Nugent K, Ortega L, Goodkin H, Roeder E, Roy S, Sapp K, Saade D, Sisodiya S, Stals K, Towner S, Wilson W, Disorders D, Borras S, Clark C, Dean J, Miedzybrodzka Z, Ross A, Tennant S, Dabir T, Donnelly D, Humphreys M, Magee A, McConnell V, McKee S, McNerlan S, Morrison P, Rea G, Stewart F, Cole T, Cooper N, Cooper-Charles L, Cox H, Islam L, Jarvis J, Keelagher R, Lim D, McMullan D, Morton J, Naik S, O’Driscoll M, Ong K, Osio D, Ragge N, Turton S, Vogt J, Williams D, Bodek S, Donaldson A, Hills A, Low K, Newbury-Ecob R, Norman A, Roberts E, Scurr I, Smithson S, Tooley M, Abbs S, Armstrong R, Dunn C, Holden S, Park S, Paterson J, Raymond L, Reid E, Sandford R, Simonic I, Tischkowitz M, Woods G, Bradley L, Comerford J, Green A, Lynch S, McQuaid S, Mullaney B, Berg J, Goudie D, Mavrak E, McLean J, McWilliam C, Reavey E, Azam T, Cleary E, Jackson A, Lam W, Lampe A, Moore D, Porteous M, Baple E, Baptista J, Brewer C, Castle B, Kivuva E, Owens M, Rankin J, Shaw-Smith C, Turner C, Turnpenny P, Tysoe C, Bradley T, Davidson R, Gardiner C, Joss S, Kinning E, Longman C, McGowan R, Murday V, Pilz D, Tobias E, Whiteford M, Williams N, Barnicoat A, Clement E, Faravelli F, Hurst J, Jenkins L, Jones W, Kumar V, Lees M, Loughlin S, Male A, Morrogh D, Rosser E, Scott R, Wilson L, Beleza A, Deshpande C, Flinter F, Holder M, Irving M, Izatt L, Josifova D, Mohammed S, Molenda A, Robert L, Roworth W, Ruddy D, Ryten M, Yau S, Bennett C, Blyth M, Campbell J, Coates A, Dobbie A, Hewitt S, Hobson E, Jackson E, Jewell R, Kraus A, Prescott K, Sheridan E, Thomson J, Bradshaw K, Dixit A, Eason J, Haines R, Harrison R, Mutch S, Sarkar A, Searle C, Shannon N, Sharif A, Suri M, Vasudevan P, Canham N, Ellis I, Greenhalgh L, Howard E, Stinton V, Swale A, Weber A, Banka S, Breen C, Briggs T, Burkitt-Wright E, Chandler K, Clayton-Smith J, Donnai D, Douzgou S, Gaunt L, Jones E, Kerr B, Langley C, Metcalfe K, Smith A, Wright R, Bourn D, Burn J, Fisher R, Hellens S, Henderson A, Montgomery T, Splitt M, Straub V, Wright M, Zwolinski S, Allen Z, Bernhard B, Brady A, Brooks C, Busby L, Clowes V, Ghali N, Holder S, Ibitoye R, Wakeling E, Blair E, Carmichael J, Cilliers D, Clasper S, Gibbons R, Kini U, Lester T, Nemeth A, Poulton J, Price S, Shears D, Stewart H, Wilkie A, Albaba S, Baker D, Balasubramanian M, Johnson D, Parker M, Quarrell O, Stewart A, Willoughby J, Crosby C, Elmslie F, Homfray T, Jin H, Lahiri N, Mansour S, Marks K, McEntagart M, Saggar A, Tatton-Brown K, Butler R, Clarke A, Corrin S, Fry A, Kamath A, McCann E, Mugalaasi H, Pottinger C, Procter A, Sampson J, Sansbury F, Varghese V, Baralle D, Callaway A, Cassidy E, Daniels S, Douglas A, Foulds N, Hunt D, Kharbanda M, Lachlan K, Mercer C, Side L, Temple I, Wellesley D, Consortium G, Ambrose J, Arumugam P, Baple E, Bleda M, Boardman-Pretty F, Boissiere J, Boustred C, Caulfield M, Chan G, Craig C, Daugherty L, de Burca A, Devereau A, Elgar G, Foulger R, Fowler T, FurióTarí P, Hackett J, Halai D, Hamblin A, Henderson S, Holman J, Hubbard T, Ibáñez K, Jackson R, Jones L, Kasperaviciute D, Kayikci M, Lahnstein L, Lawson K, Leigh S, Leong I, Lopez F, MaleadyCrowe F, Mason J, McDonagh E, Moutsianas L, Mueller M, Murugaesu N, Need A, Odhams C, Patch C, Perez-Gil D, Polychronopoulos D, Pullinger J, Rahim T, Rendon A, Riesgo-Ferreiro P, Rogers T, Ryten M, Savage K, Sawant K, Scott R, Siddiq A, Sieghart A, Smedley D, Smith K, Sosinsky A, Spooner W, Stevens H, Stuckey A, Sultana R, Thomas E, Thompson S, Tucci A, Walsh E, Watters S, Welland M, Williams E, Witkowska K, Network U, Acosta M, Adam M, Adams D, Agrawal P, Alejandro M, Alvey J, Amendola L, Andrews A, Ashley E, Azamian M, Bacino C, Bademci G, Baker E, Balasubramanyam A, Baldridge D, Bale J, Bamshad M, Barbouth D, Bayrak-Toydemir P, Beck A, Beggs A, Behrens E, Bejerano G, Bennet J, Berg-Rood B, Bernstein J, Berry G, Bican A, Bivona S, Blue E, Bohnsack J, Bonnenmann C, Bonner D, Botto L, Boyd B, Briere L, Brokamp E, Brown G, Burke E, Burrage L, Butte M, Byers P, Byrd W, Carey J, Carrasquillo O, Chang T, Chanprasert S, Chao H, Clark G, Coakley T, Cobban L, Cogan J, Coggins M, Cole F, Colley H, Cooper C, Craigen W, Crouse A, Cunningham M, D'Souza P, Dai H, Dasari S, Davids M, Dayal J, Deardorff M, Dell'Angelica E, Dhar S, Dipple K, Doherty D, Dorrani N, Douine E, Draper D, Duncan L, Earl D, Eckstein D, Emrick L, Eng C, Esteves C, Estwick T, Falk M, Fernandez L, Ferreira C, Fieg E, Findley L, Fisher P, Fogel B, Forghani I, Fresard L, Gahl W, Glass I, Godfrey R, Golden-Grant K, Goldman A, Goldstein D, Grajewski A, Groden C, Gropman A, Gutierrez I, Hahn S, Hamid R, Hanchard N, Hassey K, Hayes N, High F, Hing A, Hisama F, Holm I, Hom J, Horike-Pyne M, Huang A, Huang Y, Isasi R, Jamal F, Jarvik G, Jarvik J, Jayadev S, Johnston J, Karaviti L, Kelley E, Kennedy J, Kiley D, Kohane I, Kohler J, Krakow D, Krasnewich D, Kravets E, Korrick S, Koziura M, Krier J, Lalani S, Lam B, Lam C, Lanpher B, Lanza I, Lau C, LeBlanc K, Lee B, Lee H, Levitt R, Lewis R, Lincoln S, Liu P, Liu X, Longo N, Loo S, Loscalzo J, Maas R, Macnamara E, MacRae C, Maduro V, Majcherska M, Mak B, Malicdan M, Mamounas L, Manolio T, Mao R, Maravilla K, Markello T, Marom R, Marth G, Martin B, Martin M, Martínez-Agosto J, Marwaha S, McCauley J, McCormack C, McCray A, McGee E, Mefford H, Merritt J, Might M, Mirzaa G, Morava E, Moretti P, Morimoto M, Mulvihill J, Murdock D, Nakano-Okuno M, Nath A, Nelson S, Newman J, Nicholas S, Nickerson D, Nieves-Rodriguez S, Novacic D, Oglesbee D, Orengo J, Pace L, Pak S, Pallais J, Papp J, Parker N, Phillips J, Posey J, Potocki L, Pusey B, Quinlan A, Raskind W, Raja A, Rao D, Renteria G, Reuter C, Rives L, Robertson A, Rodan L, Rosenfeld J, Rosenwasser N, Ruzhnikov M, Sacco R, Sampson J, Samson S, Saporta M, Scott C, Schaechter J, Schedl T, Scott D, Sharma P, Shin J, Signer R, Sillari C, Silverman E, Sinsheimer J, Sisco K, Smith E, Smith K, Solem E, Solnica-Krezel L, Stoler J, Stong N, Sullivan J, Sun A, Sutton S, Sweetser D, Sybert V, Tabor H, Tamburro C, Tekin M, Telischi F, Thorson W, Tifft C, Toro C, Tran A, Tucker B, Urv T, Vanderver A, Velinder M, Viskochil D, Vogel T, Wahl C, Wallace S, Walley N, Walsh C, Walker M, Wambach J, Wan J, Wang L, Wangler M, Ward P, Wegner D, Wener M, Wenger T, Perry K, Westerfield M, Wheeler M, Whitlock J, Wolfe L, Woods J, Yamamoto S, Yang J, Yu G, Zastrow D, Zhao C, Zuchner S, Khokha M, Bönnemann C, Lucas C, Lakhani S. Biallelic CRELD1 variants cause a multisystem syndrome, including neurodevelopmental phenotypes, cardiac dysrhythmias, and frequent infections. Genetics In Medicine 2023, 26: 101023. PMID: 37947183, PMCID: PMC10932913, DOI: 10.1016/j.gim.2023.101023.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsPatient's immune cellsBlood mononuclear cellsImmune cell subtypesEarly-onset epilepsyAffected individualsInduced seizuresCardiac dysrhythmiasRecurrent infectionsClinical syndromeFrequent infectionsMononuclear cellsPatient cohortImmune cellsMultisystem syndromeHealthy donorsMultisystem disorderCardiac arrhythmiasBiallelic variantsCell subtypesDevelopmental delayGene variantsProtein overexpressionRecessive variantsMissense variantsProteome Analysis for Inflammation Related to Acute and Convalescent Infection
Sigdel T, Sur S, Boada P, McDermott S, Arlehamn C, Murray K, Bockenstedt L, Kerwin M, Reed E, Harris E, Stuart K, Peters B, Sesma A, Montgomery R, Sarwal M. Proteome Analysis for Inflammation Related to Acute and Convalescent Infection. Inflammation 2023, 47: 346-362. PMID: 37831367, PMCID: PMC10799112, DOI: 10.1007/s10753-023-01913-3.Peer-Reviewed Original ResearchC motif chemokine ligand 1C motif chemokine receptor 7Human Immunology Project ConsortiumWest Nile virusDengue virusLyme diseaseKidney transplant patientsChemokine ligand 1Chemokine receptor 7Common therapeutic interventionTumor necrosis factor receptorHost defense mechanismsNecrosis factor receptorCell surface markersConvalescent infectionTransplant patientsConvalescent phaseImmune signaturesAcute phaseConvalescent stageReceptor 7Common biological pathwaysHealthy donorsPolyomavirus infectionImmune responseHepatocellular carcinoma cell-derived small extracellular vesicle-associated CD147 serves as a diagnostic marker and promotes endothelial cell angiogenesis via the PI3K/Akt pathway
Huang D, Zhang W, Chen J, Jiao Z, Wang X, Rao D, Li W, Hu D, Xie F, Wang X, Li Z, Yi X, Wu J, Jiang Y, Wang Q, Zhong T. Hepatocellular carcinoma cell-derived small extracellular vesicle-associated CD147 serves as a diagnostic marker and promotes endothelial cell angiogenesis via the PI3K/Akt pathway. Extracellular Vesicles And Circulating Nucleic Acids 2023, 4: 532-547. PMID: 40357132, PMCID: PMC12066417, DOI: 10.20517/evcna.2023.30.Peer-Reviewed Original ResearchVascular endothelial growth factor AHepatocellular carcinomaHealthy donorsSmall extracellular vesiclesNano-flow cytometerEndothelial cell angiogenesisDiagnostic markerLiver cirrhosisPI3K/Akt pathwayCD147 expressionMatrigel plug angiogenesis assayPlasma of HCC patientsPromote angiogenesisHepatocellular carcinoma patientsCell angiogenesisEndothelial growth factor AExtracellular vesiclesGrowth factor AScratch wound healing assayHuman umbilical vein endothelial cellsProcess of HCC developmentHepatocellular carcinoma tissue samplesUmbilical vein endothelial cellsWound healing assayCell proliferation assayMicrofluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversityAnti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model
Xiao Q, Su X. Anti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model. Bio-protocol 2023, 13: e4655. PMID: 37113332, PMCID: PMC10127058, DOI: 10.21769/bioprotoc.4655.Peer-Reviewed Original ResearchCAR T cellsCD19 CAR T cellsRefractory B-cell malignanciesCell-induced tumorsChimeric antigen receptorImmune-deficient miceAnti-tumor efficacyB-cell malignanciesMouse xenograft modelTumor-killing abilityXenografted mouse modelCAR-TsT therapyHealthy donorsCD19-CARMouse modelXenograft modelTumor growthPreclinical researchTumor cellsCancer treatmentAntigen receptorMiceCellsMalignancyMachine learning identifies T cell receptor repertoire signatures associated with COVID-19 severity
Park J, Lee K, Lam S, Moon K, Fang Z, Chen S. Machine learning identifies T cell receptor repertoire signatures associated with COVID-19 severity. Communications Biology 2023, 6: 76. PMID: 36670287, PMCID: PMC9853487, DOI: 10.1038/s42003-023-04447-4.Peer-Reviewed Original ResearchConceptsCOVID-19 disease severityT cell effector functionT cell receptor repertoireT cell clonal expansionT cell adaptive immune responsesCell effector functionsCOVID-19 patientsTCR repertoire analysisAdaptive immune responsesCell receptor repertoireCOVID-19 severityCOVID-19 infectionCell clonal expansionNF-kB signalingSARS-CoV-2TCR repertoireHealthy donorsImmune responseAntiviral immunityEffector functionsViral infectionHost responseDisease severityReceptor repertoireTCR sequences
2022
Macrophage Migration Inhibitory Factor (MIF) Promotes Increased Proportions of the Highly Permissive Th17-like Cell Profile during HIV Infection
Trifone C, Baquero L, Czernikier A, Benencio P, Leng L, Laufer N, Quiroga MF, Bucala R, Ghiglione Y, Turk G. Macrophage Migration Inhibitory Factor (MIF) Promotes Increased Proportions of the Highly Permissive Th17-like Cell Profile during HIV Infection. Viruses 2022, 14: 2218. PMID: 36298774, PMCID: PMC9611675, DOI: 10.3390/v14102218.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMIF stimulationMIF treatmentIL-17AHIV infectionMIF/CD74 axisFounder HIV-1Functionality of CD4Higher IL-17AHigher MIF concentrationsMIF plasma levelsHIV-1 infectionMigration inhibitory factorPossible therapeutic targetMIF concentrationsIntracellular cytokinesR5-tropicCytokine productionIL-1βIL-6IL-8Plasma levelsHealthy donorsViral persistenceT lymphocytes
2021
Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific Clones
Glauzy S, Olson B, May CK, Parisi D, Massad C, Hansen JE, Ryu C, Herzog EL, Meffre E. Defective Early B Cell Tolerance Checkpoints in Patients With Systemic Sclerosis Allow the Production of Self Antigen–Specific Clones. Arthritis & Rheumatology 2021, 74: 307-317. PMID: 34279059, PMCID: PMC8766600, DOI: 10.1002/art.41927.Peer-Reviewed Original ResearchConceptsB cell tolerance checkpointsEarly B cell tolerance checkpointsPeripheral B cell tolerance checkpointsNaive B cellsMature naive B cellsSystemic sclerosisTransitional B cellsTolerance checkpointsB cellsHealthy donorsAutoreactive mature naive B cellsAutoreactive naive B cellsAntigen-specific B cellsCentral B cell toleranceB cell toleranceB cell productionAntigen-specific clonesReactivity of antibodiesSingle B cellsSSc patientsSerum autoantibodiesAutoimmune diseasesImmune complexesPatientsCell toleranceDetermination of 97.5th and 99th percentile upper reference limits for heart-type fatty acid-binding protein (H-FABP) in a US population
Vera MA, Koch CD, Kavsak PA, El-Khoury JM. Determination of 97.5th and 99th percentile upper reference limits for heart-type fatty acid-binding protein (H-FABP) in a US population. Clinica Chimica Acta 2021, 523: 397-401. PMID: 34666029, DOI: 10.1016/j.cca.2021.10.011.Peer-Reviewed Original ResearchConceptsHeart-type fatty acid-binding proteinUpper reference limitPercentile upper reference limitClinical utilityReference limitsAcute kidney injuryHeart-type fatty acidAcute coronary syndromeAACC Universal Sample BankFatty acid-binding proteinH-FABP concentrationHealthy U.S.Coronary syndromeFinal sample populationKidney injuryAssay cutoffHealthy donorsAcid-binding proteinUS populationImmunoturbidimetric assayPotential biomarkersClinical sensitivityMyocardial tissueSerum samplesLow molecular weight proteins
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply